Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 16/20 | 1.00 |
| ▸ | EPAS1 | Q99814 | 16/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14930301 | 0.85 | HIF1A (0.80) | HIF1AEPAS1 | |
| SCHEMBL2564584 | 0.80 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL2560662 | 0.80 | HIF1A (1.00) | HIF1AEPAS1ALDH1A1 | |
| SCHEMBL14917354 | 0.79 | HIF1A (1.00) | HIF1AEPAS1ALDH1A1 | |
| SCHEMBL2562154 | 0.79 | HIF1A (1.00) | HIF1AEPAS1ALDH1A1 | |
| SCHEMBL2561566 | 0.72 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL15682749 | 0.71 | L3MBTL1 (0.60) | HIF1AEPAS1PDE4APDE4BPDE4C | |
| SCHEMBL7418883 | 0.70 | PDE4A (0.78) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2561952 | 0.69 | HIF1A (1.00) | HIF1AEPAS1 | |
| SCHEMBL7418683 | 0.69 | PDE4A (0.80) | HIF1AEPAS1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | claimed |
| WO-2011133659-A2 | INHIBITORS OF HIF AND ANGIOGENESIS | EMORY UNIVERSITY (US) | 2011-10-27 | — | — | WO | claimed |
| US-9062072-B2 | Inhibitors of HIF and angiogenesis | EMORY UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011133659-A2 | INHIBITORS OF HIF AND ANGIOGENESIS | EMORY UNIVERSITY (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885EPAS1 16/4885PDE4A 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.